32 results on '"YANTORNO, SEBASTIÁN"'
Search Results
2. Predicting Mortality after Autologous Transplant: Development of a Novel Risk Score
3. Hematopoietic Cell Transplantation–Specific Comorbidity Index Predicts Morbidity and Mortality in Autologous Stem Cell Transplantation
4. High doses of chemotherapy and autologous hematopoietic stem cell transplantation in patients with relapsed/refractory testicular germ cell tumors: Multicenter real-world experience in Argentina.
5. Survival analysis of transplant-eligible newly-diagnosed multiple myeloma patients harboring t(4;14), t(14;16), and/or del(17p) in the real-world setting
6. Multiple Myeloma Patients Aged 40 Years and Younger Have the Same Prognosis As Older Patients in an Analysis of Real-World Evidence from Latin America: A Study of 1,316 Patients from the Gelamm Latin American Multiple Myeloma Studygroup
7. Results with allo-SCT in patients with relapsed/refractory HL treated with anti-PD-1, a multicenter retrospective cohort study: subcommittee of transplantation and cellular therapy (GATMO-TC) of the Argentinian Hematology Society (SAH)
8. High Doses of Chemotherapy and Autologous Hematopoietic STEM Cell Transplantation in Patients with Relapsed/Refractory Testicular GERM Cell Tumors. Multicenter Real-World Experience in Argentina.
9. P-176: Effect of induction regimen in survival in newly diagnosed multiple myeloma patients receiving consolidation with autologous stem cell transplantation
10. High Progression Free Survival Rates in Patients with Multiply Relapsed/Refractory Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant after Checkpoint Inhibitors: Results from Grupo Argentino De Trasplante De Medula Osea y Terapia Celular (GATMO-TC)
11. Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study
12. Real world outcomes with Bortezomib Thalidomide dexamethasone and Cyclophosphamide Bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma Múltiple
13. Bortezomib: an effective agent in extramedullary disease in multiple myeloma
14. Early mortality in Transplant-eligible Multiple Myeloma patients in Latin America. An International Study of GELAMM.
15. COMPARISON OF MATCHED SIBLING, UNRELATED AND HAPLOIDENTICAL DONORS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION. A REAL WORLD EXPERIENCE FROM THE ARGENTINE GROUP FOR BONE MARROW TRANSPLANTATION AND CELL THERAPY (GATMO-TC).
16. Real World Outcomes in Latin-American Patients with Multiple Myeloma Under 40 Years Old
17. Unequal Outcomes in Transplant Eligible Patients with Multiple Myeloma in Latin America: Differences between Public and Private Centers
18. Allogeneic Haematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia
19. The Latin American experience of allografting patients with severe aplastic anaemia: real-world data on the impact of stem cell source and ATG administration in HLA-identical sibling transplants
20. Real World Outcomes with VTD and Cybord Induction Treatment for Transplant Eligible Multiple Myeloma Patients in a Latin American Country. Retrospective Cohort Study from Gamm (Grupo Argentino de Mieloma Multiple)
21. Haploidentical transplant in adult patients with acute lymphoblastic leukemia in Argentina: a comparison with matched related and unrelated donors
22. Allogeneic stem cell transplantation improves survival in relapsed Hodgkin lymphoma patients achieving complete remission after salvage treatment
23. Successful Management of a Severe Case of Bisphosphonates Related Osteonecrosis of the Jaw in a Multiple Myeloma Patient
24. Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Argentina: Results Comparing Matched Related, Unrelated or Haploidentical Donors. a Grupo Argentino De Trasplante De Medula Osea (GATMO) Experience
25. Comparison of Outcomes after Matched Sibling, Unrelated, or Haploidentical Allogeneic Hematopoietic Cell Transplantations (HCT). a Real World Experience of Gatmo (Grupo Argentino de Trasplante de Médula Ósea)
26. HCT.CI in Autologous Stem Cell Transplantation. Predicting Early and Late Transplant Related Mortality
27. Allogeneic Stem Cell Transplantation With Reduced Intensity Conditioning Regimen In Patients With Relapsed Hodgkin´s Lymphoma
28. Is Not Age, But Comorbidities. Allogeneic Hematopoietic Stem Cell Transplantation In Patients Older Than 50 Years In Argentina
29. Long-Term Disease-Free Survival in Patients with Relapsed/Refractory Follicular Lymphoma After Autologous Stem Cell Trasplantation
30. Bortezomib: an effective agent in extramedullary disease in multiple myeloma.
31. Long-Term Experience with Allogeneic Bone Marrow Transplant (BMT) in Chronic Myeloid Leukemia
32. Donor Age Influences Graft-Versus-Host Disease Relapse-Free Survival after Allogeneic Stem Cell Transplant in Elderly Patients in Two Countries from Latin America.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.